6918 Stock Overview
Engages in the development of orthopedic trauma medical equipment products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Aplus Biotechnology Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$79.80 |
| 52 Week High | NT$96.90 |
| 52 Week Low | NT$43.85 |
| Beta | 0 |
| 1 Month Change | -2.56% |
| 3 Month Change | -6.88% |
| 1 Year Change | 77.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 59.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6918 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | -6.2% | -2.0% | -2.1% |
| 1Y | 77.3% | -5.9% | 25.6% |
Return vs Industry: 6918 exceeded the TW Medical Equipment industry which returned -5.9% over the past year.
Return vs Market: 6918 exceeded the TW Market which returned 25.6% over the past year.
Price Volatility
| 6918 volatility | |
|---|---|
| 6918 Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 3.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6918 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6918's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.aplusbio.com |
Aplus Biotechnology Corporation Limited engages in the development of orthopedic trauma medical equipment products. The company is based in New Taipei City, Taiwan.
Aplus Biotechnology Corporation Limited Fundamentals Summary
| 6918 fundamental statistics | |
|---|---|
| Market cap | NT$2.43b |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6918 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6918 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6918 perform over the long term?
See historical performance and comparisonDividends
3.4%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:22 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aplus Biotechnology Corporation Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|